Mumbai, Feb. 14 -- Revenue from operations increased 1.4% YoY to Rs 244.22 crore in Q3 FY25.

Profit before tax (PBT) fell 2.13% to Rs 75.92 crore during the quarter.

EBITDA stood at Rs 98 crore, registering de-growth of 8% as compared with Rs 105.9 crore posted in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24.

Revenue from active pharmaceutical ingredients (API) increased 3% to Rs 176.6 crore while revenue from formulation declined 1% to Rs 67.6 crore in Q3 FY25 over Q3 FY24.

In Q3 FY25, API business contributes 72% to the total revenue, while formulation business accounted for 28%.

Ankur Vaid, Joint managing director & chief executive officer, Concord Biotech, said, "...